Cancer

First Patient Dosed in Spago Nanomedical’s Clinical Phase I/IIa Study within the Tumorad(R) Program

LUND, SE / ACCESSWIRE / December 07, 2023 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the…

1 year ago

CMS Grants Transitional Pass-Through (TPT) Payment for Ambu’s aScope 5 Broncho HD Single-Use Bronchoscope

Ambu’s fifth-generation single-use bronchoscope becomes the first and only bronchoscope to be granted incremental payment by CMS, facilitating Medicare beneficiary…

1 year ago

CMS Grants Transitional Pass-Through (TPT) Payment for Ambu’s aScope 5 Broncho HD Single-Use Bronchoscope

Ambu’s fifth-generation single-use bronchoscope becomes the first and only bronchoscope to be granted incremental payment by CMS, facilitating Medicare beneficiary…

1 year ago

HFS Research recognizes CitiusTech as a Market Leader in Horizons Report: Life Sciences Service Provider 2023

PRINCETON, N.J.--(BUSINESS WIRE)--#CitiusTech--CitiusTech, a leading provider of healthcare technology services, solutions, and platforms, has been recognized as a Market Leader…

1 year ago

HFS Research recognizes CitiusTech as a Market Leader in Horizons Report: Life Sciences Service Provider 2023

PRINCETON, N.J.--(BUSINESS WIRE)--#CitiusTech--CitiusTech, a leading provider of healthcare technology services, solutions, and platforms, has been recognized as a Market Leader…

1 year ago

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure

HOUSTON, TX / ACCESSWIRE / December 6, 2023 / Every form of cancer is devastating, but the unfortunate reality is…

1 year ago

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure

HOUSTON, TX / ACCESSWIRE / December 6, 2023 / Every form of cancer is devastating, but the unfortunate reality is…

1 year ago

Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell…

1 year ago